---
title: "Iambic Therapeutics surges 8%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305028406.md"
description: "Iambic Therapeutics rose 8.29% to US$14.48. Down 12.25% from first-day open."
datetime: "2026-11-10T14:30:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305028406.md)
  - [en](https://longbridge.com/en/news/305028406.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305028406.md)
generator: "portal-rs"
---

# Iambic Therapeutics surges 8%

Iambic Therapeutics (IAM.US) surged more than **8%** during regular trading to **$14.48**.

The stock is down 12.25% from its first-day open and sits 50.83% above its 52-week low of US$9.600.

The Nasdaq Composite is down 1.28% over the past five sessions and up 7.77% year to date.

Iambic presented updated Phase 1/1b clinical trial results for its HER2 inhibitor IAM1363 at the European Society for Medical Oncology congress, showing durable responses and good tolerability in heavily pretreated patients with HER2-mutated advanced cancer.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [IAM.US](https://longbridge.com/en/quote/IAM.US.md)

## Related News & Research

- [Bank of America Names 2 'Strong Buy' Stocks With 60%+ Upside](https://longbridge.com/en/news/305294459.md)
- [Iambic Therapeutics, Inc. GAAP EPS of -$8.52 misses by $7.75, revenue of $11.4M beats by $3.11M](https://longbridge.com/en/news/305698417.md)
- [IAM: Pipeline progress and $455M pro forma cash position support planned 2027 milestones](https://longbridge.com/en/news/305676390.md)
- [Iambic Reports Durable Responses to IAM1363 in Phase 1/1b Cancer Trial](https://longbridge.com/en/news/303079364.md)
- [Iambic CEO Joins AI Drug Discovery Panel at Jefferies Global Healthcare Conference](https://longbridge.com/en/news/304855723.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**